# Zentalis Pharmaceuticals Inc. (ZNTL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.99, market value $378 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Zentalis Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -33.9%** (5-yr avg -49.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -63.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -47.4%**. Each dollar of assets produces -47.4% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%**. Revenue fell 100.0% over the last year.
- **EPS growth (1 yr): 18.0%**. Earnings per share rose 18.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 6.93** (quick 6.93). Current assets cover the next year's liabilities 6.93 times.
- **Altman Z-score: 3.32**. A Z-score of 3.32 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Zentalis Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Zentalis Pharmaceuticals Inc.; the consensus is buy, with an average price target of $6.89 (+73% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 125.4%** (YTD 195.6%, 3-mo 9.0%). The shares are up 125.4% over twelve months including dividends.
- **From 52-week high: -42.6%** (229.2% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.94** (volatility 128%). Beta of 1.94 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ZNTL · Page: https://foliofundamentals.com/stocks/zntl

Not investment advice.